This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Nutrition/ Malnutrition  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

More Harm Than Good?

Ernest Beutler, MD

JAMA. 2007;298:1329-1331.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

It was a warm summer day more than 30 years ago when my laboratory assistant and collaborator, Wanda Kuhl, showed me some unusual results. Our laboratory had devised a facile method for measuring white blood cell glucocerebrosidase activity and was performing family studies to determine the efficiency of this technique for the detection of heterozygotes for Gaucher disease. But here was a sample from an obligate heterozygote, the mother of a patient with Gaucher disease, in which the range of enzyme activity was as low as in the patient. Bone marrow examination in this 72-year-old asymptomatic parent confirmed that she also had Gaucher disease.¹ Discovery of Gaucher disease in an older, asymptomatic individual was by no means unique—the disease had previously been detected in such persons, including one person who was aged 86 years.² However, many persons homozygous for the N370S mutation associated with Gaucher disease are . . . [Full Text of this Article]

Author Affiliation: Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Carrier Screening for Gaucher Disease: Lessons for Low-Penetrance, Treatable Diseases
Shachar Zuckerman, Amnon Lahad, Amir Shmueli, Ari Zimran, Leah Peleg, Avi Orr-Urtreger, Ephrat Levy-Lahad, and Michal Sagi
JAMA. 2007;298(11):1281-1290.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Medical Outcomes of Early Newborn Screening Programs for Phenylketonuria
Brosco et al.
Pediatrics 2008;122:192-197.
ABSTRACT | FULL TEXT